A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease. The study will also evaluate the absorption and distribution of both PF-04447943 and donepezil.

Key facts

Study ID

NCT00988598

Run by

Pfizer

People needed

15

Starts

2009-10-26

Expected to finish

2010-07-05

Last updated by the study team

2020-11-19

Who can join

Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have Alzheimer's dementia with a Mini Mental State Examination score between 18-26, inclusive.
• Subjects must have a reliable caregiver.
• Subjects must be on Aricept
• Memantine is allowed if subjects are on a stable dose
• Subjects must be in reasonably good health, based on medical history, physical examination, vital signs, and ECG, with no serious or unstable disease within the past 3 months.

You may not qualify if…

• Subjects with clinically significant heart disease cannot participate.
• Subjects with a past or current history of seizures cannot participate.

Where it is running

• Glendale Adventist Medical Center — Glendale, California, United States
• University of Florida - Center for Clinical Trials Research — Gainesville, Florida, United States
• MD Clinical — Hallandale, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.